|
Oct 23
|
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
|
|
Oct 17
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023
|
|
Jul 21
|
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
|
|
Jul 21
|
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
|
|
Jul 19
|
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
|
|
Jul 18
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023
|